Porton Pharma Solutions Ltd. (SHE:300363)
China · Delayed Price · Currency is CNY 21.14
+0.21 (1.00%)
Oct 28, 2026, 10:25 AM CST
Porton Pharma Solutions Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 11,337 | 12,553 | 8,602 | 13,735 | 22,305 | 48,697 | |
Market Cap Growth | -18.42% | 45.93% | -37.37% | -38.42% | -54.20% | 145.68% |
Enterprise Value | 11,413 | 13,106 | 9,403 | 13,249 | 20,598 | 48,168 |
Last Close Price | 20.93 | 23.14 | 15.70 | 24.24 | 38.08 | 83.17 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | 130.30 | - | 51.47 | 11.12 | 92.95 |
Forward PE | 56.57 | 68.76 | 54.14 | 27.07 | 12.63 | 71.85 |
PS Ratio | 3.08 | 3.67 | 2.86 | 3.75 | 3.17 | 15.68 |
PB Ratio | 2.18 | 2.28 | 1.59 | 2.25 | 3.45 | 11.63 |
P/TBV Ratio | 2.49 | 2.61 | 1.85 | 2.62 | 4.13 | 13.64 |
P/FCF Ratio | 15.44 | 27.03 | - | - | 16.03 | - |
P/OCF Ratio | 13.33 | 16.58 | 21.21 | 21.83 | 8.70 | 101.42 |
PEG Ratio | - | 0.27 | 0.27 | 0.27 | 0.23 | 5.13 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.10 | 3.83 | 3.12 | 3.61 | 2.93 | 15.51 |
EV/EBITDA Ratio | 15.92 | 27.29 | 92.37 | 22.82 | 8.40 | 66.91 |
EV/EBIT Ratio | 41.75 | 102.31 | - | 45.39 | 9.29 | 86.65 |
EV/FCF Ratio | 15.54 | 28.22 | - | - | 14.81 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.25 | 0.28 | 0.36 | 0.32 | 0.14 | 0.18 |
Debt / EBITDA Ratio | 1.72 | 2.76 | 11.02 | 3.08 | 0.37 | 0.99 |
Debt / FCF Ratio | 1.74 | 3.25 | - | - | 0.66 | - |
Net Debt / Equity Ratio | 0.00 | 0.02 | 0.09 | 0.00 | -0.30 | -0.11 |
Net Debt / EBITDA Ratio | -0.04 | 0.21 | 4.73 | 0.01 | -0.79 | -0.66 |
Net Debt / FCF Ratio | -0.04 | 0.22 | -5.66 | -0.01 | -1.38 | 1.60 |
Asset Turnover | 0.44 | 0.39 | 0.33 | 0.38 | 0.84 | 0.56 |
Inventory Turnover | 2.99 | 3.15 | 3.10 | 2.76 | 4.10 | 3.11 |
Quick Ratio | 1.31 | 1.25 | 1.37 | 1.94 | 1.47 | 1.12 |
Current Ratio | 2.01 | 1.82 | 1.90 | 2.63 | 1.81 | 1.52 |
Return on Equity (ROE) | -2.84% | 0.56% | -6.36% | 2.79% | 36.34% | 12.55% |
Return on Assets (ROA) | 2.16% | 0.92% | -1.54% | 1.87% | 16.59% | 6.28% |
Return on Invested Capital (ROIC) | 5.62% | 0.82% | -3.73% | 3.90% | 46.32% | 15.82% |
Return on Capital Employed (ROCE) | 4.50% | 1.90% | -3.20% | 3.70% | 31.10% | 12.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.84% | 0.77% | -3.35% | 1.94% | 8.99% | 1.08% |
FCF Yield | 6.48% | 3.70% | -0.99% | -3.65% | 6.24% | -0.61% |
Dividend Yield | 0.43% | 0.39% | - | 1.94% | 2.71% | 0.22% |
Payout Ratio | - | 31.25% | - | 234.79% | 6.44% | 15.80% |
Buyback Yield / Dilution | -0.20% | 1.42% | 0.31% | -0.21% | -0.62% | 0.11% |
Total Shareholder Return | 0.23% | 1.81% | 0.31% | 1.73% | 2.08% | 0.32% |